Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.
| Autor: | Albuquerque, Joana, Silva, Diana Neto da, Padrão, Teresa, Leal-Costa, Luísa, Bizarro, Rita, Correia, Jorge, Baptista, Carlota, Machete, Madalena, Prazeres, Gil, Margarido, Inês, Fernandes, Gonçalo, Simões, Pedro, Timóteo, Teresa, Lopes, Fábio, Godinho, João, Moreira-Pinto, João, Rodrigues, Tânia, Faria, Ana, Pulido, Catarina, Cirnes, Luís |
|---|---|
| Předmět: |
THERAPEUTIC use of antineoplastic agents
GENETIC mutation COMBINATION drug therapy ONCOGENES EPIDERMAL growth factor receptors TIME METASTASIS RETROSPECTIVE studies ACQUISITION of data MONOCLONAL antibodies COLORECTAL cancer CANCER patients MEDICAL records DESCRIPTIVE statistics RESEARCH funding BODY fluid examination OVERALL survival DRUG resistance in cancer cells |
| Zdroj: | Oncologist; Mar2024, Vol. 29 Issue 3, pe337-e344, 8p |
| Abstrakt: | Background Liquid biopsy (LB) is a non-invasive tool to evaluate the heterogeneity of tumors. Since RAS mutations (RAS -mut) play a major role in resistance to antiepidermal growth factor receptor inhibitors (EGFR) monoclonal antibodies (Mabs), serial monitoring of RAS -mut with LB may be useful to guide treatment. The main aim of this study was to evaluate the prognostic value of the loss of RAS -mut (Neo RAS -wt) in LB, during the treatment of metastatic colorectal cancer (mCRC). Methods A retrospective study was conducted on patients with mCRC between January 2018 and December 2021. RAS -mut were examined in tissue biopsy, at mCRC diagnosis, and with LB, during treatment. Results Thirty-nine patients with RAS -mut mCRC were studied. LB was performed after a median of 3 lines (0-7) of systemic treatment including anti-vascular endothelial growth factor (anti-VEGF) Mabs. NeoRAS -wt was detected in 13 patients (33.3%); 9 (69.2%) of them received further treatment with anti-EGFR Mabs with a disease control rate of 44.4%. Median overall survival (OS), from the date of LB testing, was 20 months in the Neo RAS -wt group and 9 months in the persistent RAS -mut group (log-rank 2.985; P = .08), with a 12-month OS of 84.6% and 57.7%, respectively. NeoRAS -wt was identified as a predictor of survival (HR = 0.29; P = .007), with an 11-month improvement in median OS and a 71% decrease in risk of death, in heavily pretreated patients Conclusions In conclusion, monitoring clonal evolution in mCRC by LB may provide an additional treatment line for patients with Neo RAS -wt in advanced disease. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|